DGAP-News

STRATEC signed an agreement to acquire the BioSciences business of Sony DADC

DGAP-News: STRATEC Biomedical AG / Key word(s): Takeover/Acquisition
STRATEC signed an agreement to acquire the BioSciences business of Sony DADC

08.06.2016 / 14:37
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

STRATEC signed an agreement to acquire the BioSciences business of Sony
DADC

- Significantly expands product portfolio to include smart consumables
- Diversifies overall customer structure and extends value chain
- Complementary service portfolio adds recurring revenue stream
- Revenue expectation of around EUR 17 million for current financial year

Birkenfeld, June 8, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX), today signed an agreement with Sony DADC Austria AG ("Sony DADC"),
based in Anif/Salzburg, Austria, to acquire all of the shares of its
BioSciences business, Sony DADC BioSciences GmbH ("Sony DADC BioSciences"),
which is a wholly-owned subsidiary of Sony DADC. The acquisition is
expected to be completed by the end of the third quarter 2016.

Building on Sony DADC's experience in high-precision optical disc
manufacturing, Sony DADC induced 6 years ago the formation of its
BioSciences business. Sony DADC BioSciences is a leading global OEM
supplier of smart consumables for diagnostics, life sciences and medical
technology applications. The company has a unique combination of skills and
technologies including nano- and microstructuring, coating technologies,
polymer sciences, and automated assembly. Sony DADC BioSciences has a
certified production facility and a global logistics network and covers the
entire value chain, from development and design via production and quality
assurance through to logistics. The company meets all regulatory
requirements in the relevant target markets. Its customers include global
players in highly regulated markets as well as innovative start-ups.
Furthermore, the company has numerous partnerships with universities and
research institutes. Alongside its headquarters in Anif near Salzburg in
Austria, the company has sales offices in both Asia and America.

In the current financial year, ending on March 31, 2017, the company is
expected to generate sales of around EUR 17 million with slightly positive
earnings contributing to STRATECs EBIT. Based on current planning, the
management teams expect a continuously growing EBIT margin to reach the
current group's EBIT margin by 2020. Consolidation within the STRATEC group